BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wranke A, Wedemeyer H. Antiviral therapy of hepatitis delta virus infection - progress and challenges towards cure. Curr Opin Virol. 2016;20:112-118. [PMID: 27792905 DOI: 10.1016/j.coviro.2016.10.002] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Yurdaydin C, Abbas Z, Buti M, Cornberg M, Esteban R, Etzion O, Gane EJ, Gish RG, Glenn JS, Hamid S, Heller T, Koh C, Lampertico P, Lurie Y, Manns M, Parana R, Rizzetto M, Urban S, Wedemeyer H; Hepatitis Delta International Network (HDIN). Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy. J Hepatol. 2019;70:1008-1015. [PMID: 30982526 DOI: 10.1016/j.jhep.2018.12.022] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 8.3] [Reference Citation Analysis]
2 Butler EK, Rodgers MA, Coller KE, Barnaby D, Krilich E, Olivo A, Cassidy M, Mbanya D, Kaptue L, Ndembi N, Cloherty G. High prevalence of hepatitis delta virus in Cameroon. Sci Rep 2018;8:11617. [PMID: 30072752 DOI: 10.1038/s41598-018-30078-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
3 Cao J, Sun L, Aramsangtienchai P, Spiegelman NA, Zhang X, Huang W, Seto E, Lin H. HDAC11 regulates type I interferon signaling through defatty-acylation of SHMT2. Proc Natl Acad Sci U S A 2019;116:5487-92. [PMID: 30819897 DOI: 10.1073/pnas.1815365116] [Cited by in Crossref: 60] [Cited by in F6Publishing: 53] [Article Influence: 20.0] [Reference Citation Analysis]
4 Muhammad H, Tehreem A, Hammami MB, Ting PS, Idilman R, Gurakar A. Hepatitis D virus and liver transplantation: Indications and outcomes. World J Hepatol 2021; 13(3): 291-299 [PMID: 33815673 DOI: 10.4254/wjh.v13.i3.291] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Soriano V, Sherman KE, Barreiro P. Hepatitis delta and HIV infection. AIDS 2017;31:875-84. [PMID: 28121714 DOI: 10.1097/QAD.0000000000001424] [Cited by in Crossref: 23] [Cited by in F6Publishing: 9] [Article Influence: 4.6] [Reference Citation Analysis]
6 Tavanez JP, Caetano R, Branco C, Brito IM, Miragaia-Pereira A, Vassilevskaia T, Quina AS, Cunha C. Hepatitis delta virus interacts with splicing factor SF3B155 and alters pre-mRNA splicing of cell cycle control genes. FEBS J 2020;287:3719-32. [PMID: 32352217 DOI: 10.1111/febs.15352] [Reference Citation Analysis]
7 Wedemeyer H, Negro F. Devil hepatitis D: an orphan disease or largely underdiagnosed? Gut 2019;68:381-2. [PMID: 30368454 DOI: 10.1136/gutjnl-2018-317403] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
8 Binh MT, Hoan NX, Van Tong H, Giang DP, Sy BT, Toan NL, Song LH, Bang MH, Wedemeyer H, Meyer CG, Kremsner PG, Bock CT, Velavan TP. HDV infection rates in northern Vietnam. Sci Rep 2018;8:8047. [PMID: 29795302 DOI: 10.1038/s41598-018-26446-w] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
9 Etzion O. Treatment for hepatitis delta virus with the prenylation inhibitor lonafarnib: It's getting closer. Hepatology 2018;67:1198-200. [PMID: 29365356 DOI: 10.1002/hep.29807] [Reference Citation Analysis]
10 Coffin CS, Fung SK, Alvarez F, Cooper CL, Doucette KE, Fournier C, Kelly E, Ko HH, Ma MM, Martin SR, Osiowy C, Ramji A, Tam E, Villeneuve JP. Management of Hepatitis B Virus Infection: 2018 Guidelines from the Canadian Association for the Study of Liver Disease and Association of Medical Microbiology and Infectious Disease Canada. CanLivJ 2018;1:156-217. [DOI: 10.3138/canlivj.2018-0008] [Cited by in Crossref: 23] [Cited by in F6Publishing: 7] [Article Influence: 5.8] [Reference Citation Analysis]
11 Bartenschlager R, Cornberg M, Pietschmann T. [Personalized treatment of viral hepatitis of the present and the future : Hepatitis B, C, delta, and E]. Internist (Berl) 2017;58:666-74. [PMID: 28631044 DOI: 10.1007/s00108-017-0262-8] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
12 Shirazi R, Ram D, Rakovsky A, Bucris E, Gozlan Y, Lustig Y, Shaked-Mishan P, Picard O, Shemer-Avni Y, Ben-Zvi H, Halutz O, Lurie Y, Veizman E, Carlebach M, Braun M, Naftaly MC, Shlomai A, Safadi R, Mendelson E, Sklan EH, Ben-Ari Z, Mor O. Characterization of hepatitis B and delta coinfection in Israel. BMC Infect Dis 2018;18:97. [PMID: 29486716 DOI: 10.1186/s12879-018-3008-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
13 Wedemeyer H, Yurdaydin C, Hardtke S, Caruntu FA, Curescu MG, Yalcin K, Akarca US, Gürel S, Zeuzem S, Erhardt A, Lüth S, Papatheodoridis GV, Keskin O, Port K, Radu M, Celen MK, Idilman R, Weber K, Stift J, Wittkop U, Heidrich B, Mederacke I, von der Leyen H, Dienes HP, Cornberg M, Koch A, Manns MP; HIDIT-II study team. Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial. Lancet Infect Dis 2019;19:275-86. [PMID: 30833068 DOI: 10.1016/S1473-3099(18)30663-7] [Cited by in Crossref: 49] [Cited by in F6Publishing: 18] [Article Influence: 24.5] [Reference Citation Analysis]
14 Kohsar M, Landahl J, Neumann-Haefelin C, Schulze Zur Wiesch J. Human hepatitis D virus-specific T cell epitopes. JHEP Rep 2021;3:100294. [PMID: 34308324 DOI: 10.1016/j.jhepr.2021.100294] [Reference Citation Analysis]
15 Chen L, Liang J. An overview of functional nanoparticles as novel emerging antiviral therapeutic agents. Mater Sci Eng C Mater Biol Appl 2020;112:110924. [PMID: 32409074 DOI: 10.1016/j.msec.2020.110924] [Cited by in Crossref: 58] [Cited by in F6Publishing: 44] [Article Influence: 29.0] [Reference Citation Analysis]
16 Wortmann N, Höner Zu Siederdissen C, Cornberg M. [Chronic hepatitis B and D (delta) : Current and future treatments]. Internist (Berl) 2018;59:519-27. [PMID: 29761292 DOI: 10.1007/s00108-018-0432-3] [Reference Citation Analysis]
17 Chen LY, Pang XY, Goyal H, Yang RX, Xu HG. Hepatitis D: challenges in the estimation of true prevalence and laboratory diagnosis. Gut Pathog 2021;13:66. [PMID: 34717740 DOI: 10.1186/s13099-021-00462-0] [Reference Citation Analysis]
18 Gurunathan S, Qasim M, Choi Y, Do JT, Park C, Hong K, Kim JH, Song H. Antiviral Potential of Nanoparticles-Can Nanoparticles Fight Against Coronaviruses? Nanomaterials (Basel) 2020;10:E1645. [PMID: 32825737 DOI: 10.3390/nano10091645] [Cited by in Crossref: 39] [Cited by in F6Publishing: 24] [Article Influence: 19.5] [Reference Citation Analysis]
19 Cornberg M, Sandmann L, Protzer U, Niederau C, Tacke F, Berg T, Glebe D, Jilg W, Wedemeyer H, Wirth S, Höner Zu Siederdissen C, Lynen-Jansen P, van Leeuwen P, Petersen J; Collaborators:. S3-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion – (AWMF-Register-Nr. 021-11). Z Gastroenterol 2021;59:691-776. [PMID: 34255317 DOI: 10.1055/a-1498-2512] [Reference Citation Analysis]
20 Flisiak R, Jaroszewicz J, Łucejko M. siRNA drug development against hepatitis B virus infection. Expert Opin Biol Ther 2018;18:609-17. [PMID: 29718723 DOI: 10.1080/14712598.2018.1472231] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
21 Abdrakhman A, Ashimkhanova A, Almawi WY. Effectiveness of pegylated interferon monotherapy in the treatment of chronic hepatitis D virus infection: A meta-analysis. Antiviral Res. 2021;185:104995. [PMID: 33321155 DOI: 10.1016/j.antiviral.2020.104995] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Dias J, Hengst J, Parrot T, Leeansyah E, Lunemann S, Malone DFG, Hardtke S, Strauss O, Zimmer CL, Berglin L, Schirdewahn T, Ciesek S, Marquardt N, von Hahn T, Manns MP, Cornberg M, Ljunggren HG, Wedemeyer H, Sandberg JK, Björkström NK. Chronic hepatitis delta virus infection leads to functional impairment and severe loss of MAIT cells. J Hepatol 2019;71:301-12. [PMID: 31100314 DOI: 10.1016/j.jhep.2019.04.009] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 10.3] [Reference Citation Analysis]